614 related articles for article (PubMed ID: 25783183)
1. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
5. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
Daniels SL; Burghel GJ; Chambers P; Al-Baba S; Connley DD; Brock IW; Cramp HE; Dotsenko O; Wilks O; Wyld L; Cross SS; Cox A
PLoS One; 2016; 11(7):e0160174. PubMed ID: 27463681
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer.
Prajzendanc K; Domagała P; Hybiak J; Ryś J; Huzarski T; Szwiec M; Tomiczek-Szwiec J; Redelbach W; Sejda A; Gronwald J; Kluz T; Wiśniowski R; Cybulski C; Łukomska A; Białkowska K; Sukiennicki G; Kulczycka K; Narod SA; Wojdacz TK; Lubiński J; Jakubowska A
Int J Cancer; 2020 Mar; 146(5):1293-1298. PubMed ID: 31469414
[TBL] [Abstract][Full Text] [Related]
7. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
8. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
[TBL] [Abstract][Full Text] [Related]
9. Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
Arif T; Anwar N
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2395-2401. PubMed ID: 32856871
[TBL] [Abstract][Full Text] [Related]
10. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
Tian T; Shan L; Yang W; Zhou X; Shui R
Hum Pathol; 2019 Feb; 84():231-238. PubMed ID: 30339969
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
13. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
14. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
15. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
[TBL] [Abstract][Full Text] [Related]
17. Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
Morizono A; Tanabe M; Ikemura M; Sasaki T; Ushiku T; Seto Y
J Hum Genet; 2021 Aug; 66(8):785-793. PubMed ID: 33640902
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
